Physicians, nurse practitioners, or physician assistants prescribed medication to patients with OUD, while intervention ...

Merck & Co., a global pharmaceutical leader, focuses on oncology, immunology, and vaccines. Click here to check out my ...

With Eylea biosimilar competition creeping in and Roche’s Vabsymo jockeying for market share in key indications, Regeneron is ...

An investigation conducted by Canada’s National Observer finds that Bayer colluded with Canadian regulators to obstruct a ...

The potential for TL1A-targeting duvakitug to impact unmet needs of patients with ulcerative colitis (UC) and Crohn’s disease (CD), and to provide anti-fibrotic effects for a host of other diseases, ...

The European Commission opened a formal investigation over concerns foreign actors used the hugely popular video platform to interfere in Romanian presidential elections.

Regeneron's EYLEA HD met key goals in the Phase 3 QUASAR trial for macular edema after retinal vein occlusion, with FDA ...

The Phase III win could help Regeneron and Bayer expand into retinal vein occlusion, a move that the partners need to help ...

Regeneron (NASDAQ:REGN) announced Tuesday that Eylea HD, the high-dose version of its blockbuster eye care medication Eylea ...

Bayer said its eye treatment aflibercept showed positive results in a late-stage trial, including improved vision gains for ...

Kyorin Pharmaceutical Co. Ltd. has acquired Bayer AG’s phase II obstructive sleep apnea candidate, BAY-2925976, in a deal worth €85M (US$89.3 million) plus sales-based royalties and commercial ...

a biosimilar of Bayer’s aflibercept product EYLEA, based on Canadian Patent No. 2,654,510 and the 276 patent, which triggered ...